BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16151586)

  • 1. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
    Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
    Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission.
    Ferrara F; Morabito F; Latagliata R; Martino B; Annunziata M; Oliva E; Schiavone EM; Pollio F; Palmieri S; Gianfaldoni G; Leoni F
    Haematologica; 2001 Aug; 86(8):814-20. PubMed ID: 11522537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
    Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of elderly patients with acute myeloid leukemia.
    Pulsoni A; Pagano L; Latagliata R; Casini M; Cerri R; Crugnola M; De Paoli L; Di Bona E; Invernizzi R; Marmont F; Petti MC; Rigolin G; Ronco F; Spadano A; Tosti ME; Visani G; Mele A; Mandelli F
    Haematologica; 2004 Mar; 89(3):296-302. PubMed ID: 15020267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients.
    Colovic M; Colovic N; Radojkovic M; Stanisavljevic D; Kraguljac N; Jankovic G; Tomin D; Suvajdzic N; Vidovic A; Atkinson HD
    Ann Hematol; 2012 Sep; 91(9):1363-70. PubMed ID: 22592651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
    Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Elderly patients with acute myeloid leukemia: characteristics in biology, patients, and treatment].
    Wedding U; Bokemeyer C; Meran JG; ; ;
    Med Klin (Munich); 2003 Apr; 98(4):193-207. PubMed ID: 12715143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].
    Lemez P; Gáliková J; Michalová K; Dvoráková D; MacWhannell A; Zemanová Z; Stejskal J
    Vnitr Lek; 2010 Jan; 56(1):37-43. PubMed ID: 20184110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of elderly patients with AML: results of an individualized approach.
    Hernández-Boluda JC; Sierra J; Esteve J; Nomdedeu B; Montserrat E
    Haematologica; 1998 Jan; 83(1):34-9. PubMed ID: 9542321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia.
    Ferrara F; Annunziata M; Copia C; Magrin S; Mele G; Mirto S
    Haematologica; 1998 Feb; 83(2):126-31. PubMed ID: 9549923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.